AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC 50 of 0.54 µM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity In Vitro AC1-IN-1 (compound 38; HEK293 cells; 30 µM, 1 hours) shows nontoxic to this human cell line. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: HEK293 cells Concentration: 30 µM Incubation Time: 1 hours Result: Showed nontoxic to HEK293 cells. In Vivo AC1-IN-1 (5.6 mg/kg; i.v.) displays modest, yet statistically significant, antiallodynic effects at 1 h post-treatment compared to the 0 min (allodynic) time point . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male and female C57BL/6N mice (complete Freund’s adjuvant inflammatory pain model) Dosage: 5.6 mg/kg (dissolved in 10% DMSO/10% Cremaphor/80% saline) Administration: Intravenous injection; 2 hours Result: Displayed modest, yet statistically significant, antiallodynic effects. Form:Solid IC50& Target:IC 50 : 0.54 µM (AC1)